The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04144270

Enrollment

Registered

2019-10-30

Start date

2019-11-18

Completion date

2021-04-30

Last updated

2019-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder Neoplasm

Keywords

Urinary Bladder Neoplasm, Urothelium Neoplasm, Oncology, Muscle function, Sarcopenia

Brief summary

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

Interventions

OTHEREvaluation of muscle mass and muscle function

Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Informed consent * Age ≥ 18 år * Histologically verified cancer of the renal pelvis, ureter, bladder or urethra regardless of type of histology * ECOG performance status 0 - 3 * Meet the requirements for receiving oncological treatment (neoadjuvant chemotherapy for localized disease, chemotherapy or immunotherapy for disseminated disease).

Exclusion criteria

* Age \< 18

Design outcomes

Primary

Measure	Time frame	Description
Muscle mass	Up to 36 months	We will describe if muscle mass at baseline is correlated to completion of planned systemic oncological treatment

Secondary

Measure	Time frame	Description
Muscle strength	Up to 36 months	We will describe if muscle strength at baseline is correlated to completion of planned systemic oncological treatment
Muscle mass changes during systemic oncological treatment	Up to 36 months	We will describe if muscle mass change during systemic oncological treatment
Muscle strength changes during systemic oncological treatment	Up to 36 months	We will describe if muscle mass change during systemic oncological treatment

Countries

Denmark

Contacts

Primary ContactLise Hoej Omland, MD

lise.hoej.omland@regionh.dk+45 35450782

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026